teleo/teleo-codex
8
0
Fork 0
Code Issues 22 Pull requests 16 Projects Releases Packages Wiki Activity Actions 145
teleo-codex/entities/health/exenatide-pd3-trial.md
Teleo Agents 1206c5b7a3 vida: extract claims from 2026-05-08-exenatide-parkinsons-phase3-lancet-failure 
- Source: inbox/queue/2026-05-08-exenatide-parkinsons-phase3-lancet-failure.md
- Domain: health
- Claims: 0, Entities: 1
- Enrichments: 2
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>
2026-05-08 04:28:38 +00:00

2.8 KiB
Raw Blame History

type entity_type name domain status
entity research_program Exenatide-PD3 Trial health completed

Exenatide-PD3 Trial

Type: Phase 3 randomized controlled trial
Drug: Exenatide (GLP-1 receptor agonist)
Indication: Parkinson's disease (disease-modifying therapy)
Design: Multicenter, double-blind, placebo-controlled, n=194, 96 weeks
Sites: 6 UK research hospitals
Funding: National Institute for Health and Care Research (NIHR)
Primary Endpoint: Movement symptom progression (motor function)
Status: Failed (February 2025)

Overview

Exenatide-PD3 was the largest and longest GLP-1 receptor agonist trial in Parkinson's disease to date. It tested whether exenatide once-weekly could slow disease progression by providing neuroprotection to dopaminergic neurons in the substantia nigra.

Results

Primary endpoint: FAILED — exenatide did not stop movement symptoms from worsening over 96 weeks versus placebo.

Secondary endpoints: FAILED — no benefit in non-motor symptoms (quality of life, cognition, mood) compared to placebo.

DaT-SPECT imaging: No significant change versus placebo. This biomarker tracks dopaminergic neuron degeneration; zero signal indicates no neuroprotection at the structural level.

CSF analysis (mechanistic finding): Only small amounts of exenatide reached the substantia nigra, the brain region affected by Parkinson's. This suggests insufficient CNS penetration to the target region, despite exenatide crossing the blood-brain barrier in other areas.

Context

This trial directly contradicts earlier Phase 2 work (Foltynie group, n=59) which showed significant motor benefit at 9 months (P=0.001). The Phase 3 failure raises questions about:

  • Phase 2 selection bias or underpowering
  • Regional brain penetrance as the limiting factor (not BBB crossing per se)
  • Whether the Phase 2 signal was spurious

Implications

The failure complicates the GLP-1 neuroprotection hypothesis. Two other GLP-1 agonists (semaglutide, liraglutide) remain in ongoing Phase 3 trials for Parkinson's. The CSF finding suggests that different GLP-1 agonists with distinct CNS penetration mechanisms (e.g., semaglutide via albumin binding → tanycytes) may achieve different substantia nigra concentrations and potentially different outcomes.

Expert Response

Dr. Katherine Fletcher (Parkinson's UK): "Really disappointing news" and "a setback." Concerns raised that the failure may impact funding for other GLP-1 trials in Parkinson's.

Timeline

  • 2025-02-04 — Phase 3 results published in The Lancet: all endpoints failed, CSF analysis reveals insufficient substantia nigra penetration

References